BioNTech (NASDAQ:BNTX) Releases Earnings Results, Beats Estimates By $0.70 EPS

BioNTech (NASDAQ:BNTX) posted its quarterly earnings results on Monday. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70, RTT News reports. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the previous year, the firm earned $1.90 EPS. BioNTech’s revenue was down 19.5% on a year-over-year basis. BioNTech updated its FY 2025 guidance to EPS.

BioNTech Stock Performance

Shares of BNTX opened at $105.35 on Tuesday. The stock has a 50 day moving average of $116.76 and a 200 day moving average of $113.06. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a market capitalization of $25.26 billion, a price-to-earnings ratio of -50.17 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a research report on Monday, November 18th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Wells Fargo & Company initiated coverage on BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective on the stock. Berenberg Bank initiated coverage on BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective on the stock. Finally, Truist Financial assumed coverage on BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.